Compare Gilead Sciences, Inc. (GILD) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs KraneShares CSI China Internet ETF — how do they compare? Gilead Sciences, Inc. trades at $134.55 (market cap $163.51B), while KraneShares CSI China Internet ETF trades at $27.55. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while KraneShares CSI China Internet ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| GILD | KWEB | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $42.94 |
52-Week Low | $108.22 | $23.63 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
KWEB, the KraneShares CSI China Internet ETF, trades at $27.57 with a strong 5.31% daily gain. Technical indicators show bullish momentum with moving averages supporting upward trends, though RSI levels above 80 suggest potential overbought conditions. The ETF focuses on Chinese internet and AI companies, benefiting from China's $295 billion AI infrastructure plan and strong export growth in technology sectors.
While KWEB offers exposure to China's growing tech sector at attractive valuations relative to Western peers, investors face significant geopolitical risks from US-China tensions and regulatory uncertainties. The ETF's performance remains heavily dependent on China's economic policies and international relations, creating both opportunity and volatility for US investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
